The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform
Jun Zhang - One of the best experts on this subject based on the ideXlab platform.
-
when does a supply chain member benefit from vendor managed inventory
Production and Operations Management, 2018Co-Authors: Ruixia Shi, Jun ZhangAbstract:Enabled by the advances in information technology (IT), many supply chain partners have adopted the practice of vendor†managed inventory (VMI) to improve operations efficiency. While the IT investment for VMI implementation can be significant, the benefits of VMI to different supply chain members are not obvious based on anecdotal evidences and empirical studies. This paper studies the effects of VMI on a supply chain consisting of one manufacturer and one retailer to shed light on when an IT investment for VMI adoption can be justified. We show that whether the two supply chain members benefit from VMI depends on how the holding or shortage Cost Increment from the manufacturer to retailer compares with two corresponding critical values. We then develop comparative statics results on how these critical values change with respect to different parameters. Interestingly, the retailer is more likely to benefit from the adoption of VMI when its inventory holding Cost is low, and the manufacturer is more likely to benefit from VMI adoption when its inventory holding Cost is high, contradicting what our intuitions would suggest and what has been prescribed in the literature.
-
When Does A Supply Chain Member Benefit from Vendor‐Managed Inventory?
Production and Operations Management, 2018Co-Authors: Ruixia Shi, Jun ZhangAbstract:Enabled by the advances in information technology (IT), many supply chain partners have adopted the practice of vendor†managed inventory (VMI) to improve operations efficiency. While the IT investment for VMI implementation can be significant, the benefits of VMI to different supply chain members are not obvious based on anecdotal evidences and empirical studies. This paper studies the effects of VMI on a supply chain consisting of one manufacturer and one retailer to shed light on when an IT investment for VMI adoption can be justified. We show that whether the two supply chain members benefit from VMI depends on how the holding or shortage Cost Increment from the manufacturer to retailer compares with two corresponding critical values. We then develop comparative statics results on how these critical values change with respect to different parameters. Interestingly, the retailer is more likely to benefit from the adoption of VMI when its inventory holding Cost is low, and the manufacturer is more likely to benefit from VMI adoption when its inventory holding Cost is high, contradicting what our intuitions would suggest and what has been prescribed in the literature.
Ruixia Shi - One of the best experts on this subject based on the ideXlab platform.
-
when does a supply chain member benefit from vendor managed inventory
Production and Operations Management, 2018Co-Authors: Ruixia Shi, Jun ZhangAbstract:Enabled by the advances in information technology (IT), many supply chain partners have adopted the practice of vendor†managed inventory (VMI) to improve operations efficiency. While the IT investment for VMI implementation can be significant, the benefits of VMI to different supply chain members are not obvious based on anecdotal evidences and empirical studies. This paper studies the effects of VMI on a supply chain consisting of one manufacturer and one retailer to shed light on when an IT investment for VMI adoption can be justified. We show that whether the two supply chain members benefit from VMI depends on how the holding or shortage Cost Increment from the manufacturer to retailer compares with two corresponding critical values. We then develop comparative statics results on how these critical values change with respect to different parameters. Interestingly, the retailer is more likely to benefit from the adoption of VMI when its inventory holding Cost is low, and the manufacturer is more likely to benefit from VMI adoption when its inventory holding Cost is high, contradicting what our intuitions would suggest and what has been prescribed in the literature.
-
When Does A Supply Chain Member Benefit from Vendor‐Managed Inventory?
Production and Operations Management, 2018Co-Authors: Ruixia Shi, Jun ZhangAbstract:Enabled by the advances in information technology (IT), many supply chain partners have adopted the practice of vendor†managed inventory (VMI) to improve operations efficiency. While the IT investment for VMI implementation can be significant, the benefits of VMI to different supply chain members are not obvious based on anecdotal evidences and empirical studies. This paper studies the effects of VMI on a supply chain consisting of one manufacturer and one retailer to shed light on when an IT investment for VMI adoption can be justified. We show that whether the two supply chain members benefit from VMI depends on how the holding or shortage Cost Increment from the manufacturer to retailer compares with two corresponding critical values. We then develop comparative statics results on how these critical values change with respect to different parameters. Interestingly, the retailer is more likely to benefit from the adoption of VMI when its inventory holding Cost is low, and the manufacturer is more likely to benefit from VMI adoption when its inventory holding Cost is high, contradicting what our intuitions would suggest and what has been prescribed in the literature.
Gene Barnett - One of the best experts on this subject based on the ideXlab platform.
-
The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible
Cost Effectiveness and Resource Allocation, 2016Co-Authors: Jeffrey D. Voigt, Gene BarnettAbstract:Background The objective of this analysis was to determine the value (Incremental Cost/Increment benefit) of a brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open resection (i.e. craniotomy) methods or biopsy (collectively termed CURRENT TREATMENTS) in patients where maximal safe resection may not be feasible. As has been demonstrated in the literature, extent of resection/ablation with minimal complications are independently related to overall survival. Methods A Cost effectiveness analysis from a societal perspective was employed using TreeAge Pro 2014 software. Direct Costs (using national average Medicare reimbursement amounts), outcomes (overall survival), and value [defined as Increment Cost/Incremental survival—evaluated as Cost/life year gained (LYG)] were evaluated. Sensitivity analysis was also performed to determine which variables had the largest effect on Incremental Costs and outcomes. Results In the base case, the overall survival was improved with brain LITT versus CURRENT TREATMENTS by 3.07 months at an additional Cost of $7508 (or $29,340/LYG). This amount was significantly less than the current international threshold value for $32,575/LYG and considerably less than the US threshold value of $50,000/LYG. This Incremental Cost may also qualify under NICE criteria for end of life therapies. In sensitivity analysis: As percent local recurrence GBM increased; Cost of DRG25/26 increased; percent GTR increased; and gliadel use increased—the value of brain LITT improved. Additionally, in those patients where a biopsy is the only option, brain LITT extended life by 7 months. Conclusions Brain LITT should be considered a viable option for treatment of high grade gliomas as it improves survival at a Cost which appears to be of good value to society. This Incremental Cost is less than the international and US thresholds for good value.
-
The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible
Cost effectiveness and resource allocation : C E, 2016Co-Authors: Jeffrey D. Voigt, Gene BarnettAbstract:The objective of this analysis was to determine the value (Incremental Cost/Increment benefit) of a brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open resection (i.e. craniotomy) methods or biopsy (collectively termed CURRENT TREATMENTS) in patients where maximal safe resection may not be feasible. As has been demonstrated in the literature, extent of resection/ablation with minimal complications are independently related to overall survival. A Cost effectiveness analysis from a societal perspective was employed using TreeAge Pro 2014 software. Direct Costs (using national average Medicare reimbursement amounts), outcomes (overall survival), and value [defined as Increment Cost/Incremental survival—evaluated as Cost/life year gained (LYG)] were evaluated. Sensitivity analysis was also performed to determine which variables had the largest effect on Incremental Costs and outcomes. In the base case, the overall survival was improved with brain LITT versus CURRENT TREATMENTS by 3.07 months at an additional Cost of $7508 (or $29,340/LYG). This amount was significantly less than the current international threshold value for $32,575/LYG and considerably less than the US threshold value of $50,000/LYG. This Incremental Cost may also qualify under NICE criteria for end of life therapies. In sensitivity analysis: As percent local recurrence GBM increased; Cost of DRG25/26 increased; percent GTR increased; and gliadel use increased—the value of brain LITT improved. Additionally, in those patients where a biopsy is the only option, brain LITT extended life by 7 months. Brain LITT should be considered a viable option for treatment of high grade gliomas as it improves survival at a Cost which appears to be of good value to society. This Incremental Cost is less than the international and US thresholds for good value.
Jeffrey D. Voigt - One of the best experts on this subject based on the ideXlab platform.
-
The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible
Cost Effectiveness and Resource Allocation, 2016Co-Authors: Jeffrey D. Voigt, Gene BarnettAbstract:Background The objective of this analysis was to determine the value (Incremental Cost/Increment benefit) of a brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open resection (i.e. craniotomy) methods or biopsy (collectively termed CURRENT TREATMENTS) in patients where maximal safe resection may not be feasible. As has been demonstrated in the literature, extent of resection/ablation with minimal complications are independently related to overall survival. Methods A Cost effectiveness analysis from a societal perspective was employed using TreeAge Pro 2014 software. Direct Costs (using national average Medicare reimbursement amounts), outcomes (overall survival), and value [defined as Increment Cost/Incremental survival—evaluated as Cost/life year gained (LYG)] were evaluated. Sensitivity analysis was also performed to determine which variables had the largest effect on Incremental Costs and outcomes. Results In the base case, the overall survival was improved with brain LITT versus CURRENT TREATMENTS by 3.07 months at an additional Cost of $7508 (or $29,340/LYG). This amount was significantly less than the current international threshold value for $32,575/LYG and considerably less than the US threshold value of $50,000/LYG. This Incremental Cost may also qualify under NICE criteria for end of life therapies. In sensitivity analysis: As percent local recurrence GBM increased; Cost of DRG25/26 increased; percent GTR increased; and gliadel use increased—the value of brain LITT improved. Additionally, in those patients where a biopsy is the only option, brain LITT extended life by 7 months. Conclusions Brain LITT should be considered a viable option for treatment of high grade gliomas as it improves survival at a Cost which appears to be of good value to society. This Incremental Cost is less than the international and US thresholds for good value.
-
The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible
Cost effectiveness and resource allocation : C E, 2016Co-Authors: Jeffrey D. Voigt, Gene BarnettAbstract:The objective of this analysis was to determine the value (Incremental Cost/Increment benefit) of a brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open resection (i.e. craniotomy) methods or biopsy (collectively termed CURRENT TREATMENTS) in patients where maximal safe resection may not be feasible. As has been demonstrated in the literature, extent of resection/ablation with minimal complications are independently related to overall survival. A Cost effectiveness analysis from a societal perspective was employed using TreeAge Pro 2014 software. Direct Costs (using national average Medicare reimbursement amounts), outcomes (overall survival), and value [defined as Increment Cost/Incremental survival—evaluated as Cost/life year gained (LYG)] were evaluated. Sensitivity analysis was also performed to determine which variables had the largest effect on Incremental Costs and outcomes. In the base case, the overall survival was improved with brain LITT versus CURRENT TREATMENTS by 3.07 months at an additional Cost of $7508 (or $29,340/LYG). This amount was significantly less than the current international threshold value for $32,575/LYG and considerably less than the US threshold value of $50,000/LYG. This Incremental Cost may also qualify under NICE criteria for end of life therapies. In sensitivity analysis: As percent local recurrence GBM increased; Cost of DRG25/26 increased; percent GTR increased; and gliadel use increased—the value of brain LITT improved. Additionally, in those patients where a biopsy is the only option, brain LITT extended life by 7 months. Brain LITT should be considered a viable option for treatment of high grade gliomas as it improves survival at a Cost which appears to be of good value to society. This Incremental Cost is less than the international and US thresholds for good value.
Beatriz Martinezpastor - One of the best experts on this subject based on the ideXlab platform.
-
resilience of traffic networks from perturbation to recovery via a dynamic restricted equilibrium model
Reliability Engineering & System Safety, 2016Co-Authors: Maria Nogal, Alan Oconnor, Brian Caulfield, Beatriz MartinezpastorAbstract:Abstract When a disruptive event takes place in a traffic network some important questions arise, such as how stressed the traffic network is, whether the system is able to respond to this stressful situation, or how long the system needs to recover a new equilibrium position after suffering this perturbation. Quantifying these aspects allows the comparison of different systems, to scale the degree of damage, to identify traffic network weaknesses, and to analyse the effect of user knowledge about the traffic network state. The indicator that accounts for performance and recovery pattern under disruptive events is known as resilience. This paper presents a methodology to assess the resilience of a traffic network when a given perturbation occurs, from the beginning of the perturbation to the total system recovery. To consider the dynamic nature of the problem, a new dynamic equilibrium-restricted assignment model is presented to simulate the network performance evolution, which takes into consideration important aspects, such as the Cost Increment due to the perturbation, the system impedance to alter its previous state and the user stress level. Finally, this methodology is used to evaluate the resilience indices of a real network.
